Search results
Results from the WOW.Com Content Network
Financials as of September 30, 2023. [update] [1] Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. [2]
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4. AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View Skip ...
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe. Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Steven H. Collis (born 1961) is an American businessman, the chairman, president and chief executive officer (CEO) of Cencora, previously known as AmerisourceBergen. Early life. Collis was born in South Africa and attended the University of Witwatersrand, where he earned a Bachelor of Commerce. Collis is Jewish. Career
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.